Nuevas tecnologías, aliadas en el tratamiento de la Esclerosis Múltiple
La tecnología está mostrando avances importantes en el tratamiento de esta enfermedad, pero aún existen retos en Colombia paragarantizar el acceso, atención integral e inclusión de la población afectada. También, se requiere una mayor empatía en la relación médico-paciente.
Gabriel Pardo
MD, FAAN, is the Director of the Oklahoma Medical Research Foundation Multiple Sclerosis (MS) Center of Excellence, and Associate Member of the OMRF Arthritis and Clinical Immunology Research Program. He is an ophthalmologist, neurologist and neuroophthalmologist, being board certified by the American Board of Psychiatry and Neurology. In addition, Dr Pardo serves on many national professional committees, including the National Clinical Advisory Board of the National MS Society. His research interests focus on identifying objectives markers of disease activity or progression, advanced clinical and translational research, and optimization of ambulatory function. His clinical goals include providing MS patients with access to multidisciplinary comprehensive care, educational seminars, clinical trials, and clinical research in order to ensure successful treatment outcomes. His research has been widely published, and he serves as a reviewer for several major peer-reviewed biomedical journals. In addition to his numerous accomplishments pertaining to MS research, he was inducted into the Volunteer Hall of Fame of the National MS Society under the Health Professionals/Research category and received the Labe C Scheinberg award from the CMSC Foundation.
Estefania Florez
Maria Isabel Zuluaga